- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| Di | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA for U.S. study | 4 | Stockwatch | ||
| Di | PharmAla signs MDMA supply deal with Nautilus Sanctuary | 1 | Investing.com | ||
| Fr | Pharmala Biotech Holdings Inc: Pharmala signs drug donation deal with Spaulding | 3 | Stockwatch | ||
| Do | PharmAla Biotech: PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia | 1 | GlobeNewswire (USA) | ||
| 24.02. | Pharmala Biotech Holdings Inc: Pharmala signs supply deal with Amsterdam UMC | 2 | Stockwatch | ||
| 23.02. | PharmAla Biotech: PharmAla To Supply Amsterdam UMC with LaNeo MDMA, Including Development of New Single-Capsule Stability Data | 229 | GlobeNewswire (Europe) | TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo MDMA and... ► Artikel lesen | |
| 11.02. | Pharmala Biotech Holdings Inc: Pharmala Biotech appoints Ryer as director | 2 | Stockwatch | ||
| 10.02. | PharmAla Biotech announces board changes, appoints new director | 1 | Investing.com | ||
| 10.02. | PharmAla Biotech: PharmAla Announces Changes to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 09.01. | Pharmala Biotech Holdings Inc: Pharmala to supply LaNeo for Ostfold clinical research | 2 | Stockwatch | ||
| 08.01. | PharmAla Biotech: PharmAla To Supply Østfold Hospital Trust with LaNeo MDMA for Clinical Research | 1 | GlobeNewswire (USA) | ||
| 24.12.25 | Pharmala Biotech Holdings Inc: Pharmala Biotech files fiscal 2025, Q1 2026 financials | 4 | Stockwatch | ||
| 24.12.25 | PharmAla Biotech: PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements | 252 | GlobeNewswire (Europe) | TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 16.12.25 | Pharmala Biotech Holdings Inc: Pharmala Biotech Australia hires CDMO for manufacturing | 1 | Stockwatch | ||
| 11.12.25 | Pharmala Biotech Holdings Inc: Pharmala completes release testing on LaNeo capsules | 1 | Stockwatch | ||
| 10.12.25 | PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules | 1 | GlobeNewswire (USA) | ||
| 04.11.25 | Pharmala Biotech Holdings Inc: Pharmala Biotech files final prospectus | 1 | Stockwatch | ||
| 03.11.25 | PharmAla Biotech: PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital | 233 | GlobeNewswire (Europe) | TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 09.10.25 | Pharmala Biotech Holdings Inc: Pharmala launches Nexus chain-of-care portal | 1 | Stockwatch | ||
| 08.10.25 | PharmAla Biotech: PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,875 | +0,43 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIONTECH | 89,00 | +2,59 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,580 | +24,68 % | Needham lowers Day One Biopharmaceuticals price target on costs | ||
| ADMA BIOLOGICS | 16,380 | -1,21 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| MODERNA | 50,19 | +17,01 % | Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung | Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 86,64 | -3,84 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften | ||
| EVOTEC | 5,652 | +6,56 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| ARCELLX | 114,28 | +0,25 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| TYRA BIOSCIENCES | 35,450 | +9,01 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| ERASCA | 15,090 | +4,83 % | Erasca, Inc. (ERAS): A Bull Case Theory | ||
| COGENT BIOSCIENCES | 37,305 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,980 | +1,56 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen | |
| OCUGEN | 1,670 | +5,13 % | Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results | Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial-the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients-was completed. Topline Phase 3 data expected... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,695 | +6,64 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen | |
| IMMUNITYBIO | 7,992 | -7,20 % | Piper Sandler raises Immunitybio stock price target on revenue growth |
PHARMALA BIOTECH HOLDINGS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.